Featured
Featured posts

0 3499
Marijuana-Stocks- cannabis-trump

Finding a U.S. Secret Service candidate with no history of smoking cannabis has become so rare that the agency’s new director, Randolph Alles has decided to become more lenient on the issue. Alles announced last week that his office would relax their drug policy for potential new recruits.

At a recent press briefing, the three-month experienced director spoke to reporters stating that it has become increasingly more difficult to find applicants as the majority of them have a history with cannabis.

Due to this, as of last month, the Secret Service agency has changed its policy in favor of marijuana. The new policy states that the agency will not disqualify potential candidates simply due to their history with marijuana. Rather, they will take into consideration solely their current states with the plant.

Applicants twenty-four and under only have to show that they have not used the cannabis for at least twelve months. Applicants who are twenty-eight years and older are required to not have used it within at least five years.

Despite being more lenient to candidates who have smoked in the past, Alles stated that the Secret-Service Agency would still conduct a strict interview process including an in-depth background check as well as a lie detector (polygraph) test.

Due to the fact that marijuana use has skyrocketed in the past ten years with many states legalizing the medicinal plant, the attitude toward it has become more relaxed. Alles and his agency realized that it would be impossible to find qualified applicants who had not smoked marijuana in the past.

Alles stated that the office employs several thousands of people and would not be able to find a steady stream of possible employees without changing their harsh policy. The new policy is expected to result in the hiring of over ten thousand new employees over the course of the next few years.

With the current state of the presidency, Alles, according to CNN stated that “We need more people. The mission has changed.”

The speculation is that the Secret Service, who’s job is to provide not only security for the president and his family, but also investigate financial crimes, is having an increase in hiring to deal with the rise in anti-Trump cases expected to occur over the next four years.

The agency has many issues in the modern world to combat with its massive body of agents, but without a viable pool of candidates, the agency would see a steady decline.

0 1025
Marijuana Stocks Cannabis Stocks

Although the biotech sector of the cannabis industry offers investors great opportunity and is comprised of some of the most mature public companies, we expect it to remain under pressure following the Nasdaq’s plunge on Friday.

On Friday, the Nasdaq hit a record high before it ended the day down 1.8% and the tech sector is poised to tumble even further today.

Goldman Sachs Issues Valuation Warning

The Nasdaq’s plunge follows a report from Goldman Sachs that included a valuation warning on stocks such as Facebook, Amazon, Apple, Microsoft and Alphabet. Goldman’s report looked at the influence of these five stocks which have collectively added $600 billion in market cap this year, equal to the combined gross domestic product (GDP) of Hong Kong and South Africa.

Goldman’s Robert Bouroujerdi writes that “while FANG has dominated investor focus, the nature of the acronym has expanded more broadly to encompass mega-cap tech. Indeed, the bigger story in our view is FAAMG – Facebook, Amazon, Apple, Microsoft and Alphabet – a group of five stocks which have been the key drivers of both the SPX & NDX returns year-to date. This outperformance, driven by secular growth and the death of the reflation narrative, has created positioning extremes, factor crowding and difficult-to-decipher risk narratives (e.g. FAAMG’s realized volatility is now below that of Staples and Utilities).”

Weakness Creates Opportunity

Although we expect biotech cannabis stocks trade lower with the Nasdaq, this weakness will create opportunity for investors and we want to highlight three companies to monitor during this time.

Insys Therapeutics (INSY) has fallen almost 20% in the last week and we expect the shares to remain under significant pressure after Endo Pharmaceuticals (ENDP) was asked to remove their painkiller from the market.

Last week, Insys’ former manager of reimbursement services, Elizabeth Gurrieri pled guilty to one count of wire fraud conspiracy and we expect this trend to continue with the other former managers and executives indicted. Insys is at the center of a Fentanyl crisis in the United States and we expect the shares to continue to trade lower over the near term.

Although we are concerned with Insys, we view Insys as an acquisition candidate and expect to see the company acquired this year. In July 2016, INSY announced that the FDA approved Syndros, an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of THC. At the time of this announcement, INSY said that Syndros is awaiting scheduling by the DEA.

India Globalization Capital (IGC) is one of the few cannabis-focused companies that trade on the New York Stock Exchange (NYSE) and today, the company entered a definitive license agreement with the University of South Florida (USF). Under the agreement, IGC is the exclusive licensee of the U.S. patent filing entitled, THC as a Potential Therapeutic Agent for Alzheimer’s Disease.

This is an important development and milestone for the company as it works toward the development of a potential cannabis-based blockbuster treatment for America’s most expensive disease, Alzheimer’s disease.

A lot of IGC’s value is in the intellectual property and its previously filed patents. In September 2014, the company filed a patent for IGC-501 and IGC is currently finalizing the product development by conducting anecdotal testing. In August 2014, the company filed a patent for IGC-504 and in February 2017, IGC filed a patent for IGC-506. The company expects to file an additional patent to finalize these products later this year while advancing its refractory epilepsy treatment for dogs and cats (IGC-505 and IGC-503).

We are favorable on IGC’s recent updates as it has pivoted fully into the biotech cannabis sector and will monitor how the market responds to this news. We have IGC on our watch list and continue to monitor developments around the company’s cannabinoid-based therapies.

GW Pharmaceuticals (GWPH) has come off its recent lows and the shares are trading near $95. GW is trading at oversold levels after falling 30% from its 2017 highs and the company has several catalysts occurring in the second half of this year.

GW is changing the landscape of the biotech industry and the company already sells a cannabis-derived treatment for multiple sclerosis is 27 countries. GW is a company that investors need to watch as it continues to execute on its pipeline and create value for shareholders.

We consider GW Pharma to be one of the top long-term cannabis investments due to the following reasons: 1) It has the largest pipeline of products in advanced stages of FDA testing; 2) it has significant Wall Street coverage; 3) The company is led by a management team that continues to execute and create value for its shareholders; 4) GW owns some of the most valuable IP in the cannabis industry; and 5) The company has enough cash to cover the costs of its New Drug Application and Clinical trials.

 

Authored By: Micheal Berger

0 1448
Marijuana-stocks-california repbublic

Los Angeles uncovered a new set of proposed regulations this past Thursday on how and where marijuana businesses can operate within city limits, the latest step toward reworking its rules after Californians voted to legalize recreational pot.

The draft rules would impose restrictions on where pot shops that sell marijuana to customers on site can operate, limiting them to most commercial and industrial zones and barring them from opening within 800 feet of one another.

Marijuana retailers would also be prohibited from operating within 800 feet of schools, public libraries, parks and drug and alcohol treatment facilities. Other kinds of marijuana businesses, including indoor cultivation facilities, would be restricted to most industrial zones.

City officials also released a set of proposed regulations on application requirements and operating rules for cannabis businesses. Those draft rules prohibit marijuana or alcohol from being consumed on site, require security and video surveillance, and mandate that businesses allow inspections and audits, among many other requirements.

To apply to operate in Los Angeles, cannabis businesses would have to provide detailed information about their ownership, loans and investors. Marijuana shops that registered to pay business taxes this or last year and are in “substantial compliance” with an earlier set of restrictions would be first in line to get city certificates.

The proposed rules also impose some hiring and labor requirements: Marijuana businesses must set forward a detailed plan for hiring local residents when they apply to operate in L.A. If they have at least 10 employees, they must have a “labor peace agreement.” Such agreements prohibit employers from interfering with any potential labor organizing by their employees, said Vanessa Rodriguez, a spokeswoman for City Council President Herb Wesson.

The draft regulations will be available for public review and comment for 60 days before city officials take any action. “We will continue to have a robust dialogue about the regulatory framework and a healthy debate of Los Angeles’ growing cannabis industry” before the council votes on final recommendations, Wesson said in a written statement Thursday.

Cannabis industry and advocacy groups applauded the city for taking the step but said they were still reviewing the proposed rules.

0 627
marijuana-stocks-cannabis-jar-1

Medical marijuana dispensaries are beginning to open in Hawaii, but they’re not allowed to sell their products. Instead, the leafy medicinal greens they’ve grown are sitting on a shelf unsold because nearly a year after dispensaries were legally allowed to open, the state has not yet certified any labs to run required safety tests.

That means dispensaries such as Aloha Green on Oahu have no income despite payroll, rent and operations expenses that top $100,000 a month.

“For us it’s a little frustrating, having so many people on board, but it has to be done,” said James H.Q. Lee, CEO of Aloha Green. “I’m more concerned for the patients because people have been calling: ‘We see it online, when are you going to open? We need our medical cannabis.’”

Hawaii was among the first states to legalize medical marijuana 17 years ago, but dispensaries were only legalized in 2015. The state’s 17,000 registered patients have been left to grow marijuana plants on their own or buy it on the black market. The delays have been frustrating to potential customers, executives and employees in the nascent industry.

Since they’re paying for the space, Aloha Green decided to open their doors to the public Thursday for education and outreach.

“That’s indicative of how creative the licensees are having to be because they’re bleeding money,” said Carl Bergquist, executive director of the Drug Policy Forum of Hawaii.

By law, dispensaries were allowed to open in July 2016, but none could open their doors or even begin growing cannabis because the state had not approved software to track the product from seed-to-sale.

“People are hoping for dispensaries to open, but they’re just waiting and waiting,” said Jari Sugano, whose 8-year-old daughter suffers from a form of severe epilepsy that can be treated with medical cannabis. “In the end, the delays are going to come back on the patient to pay back.”

But state officials and lawmakers say they’re working as fast as they can to set up an industry from scratch while ensuring patient safety.

“The dates that were in the legislation were unrealistic,” said Keith Ridley of the Department of Health. “I think we need to reset our timeframes.”

Nationwide, it often takes states a year-and-a-half to two years to open medical marijuana dispensaries after passing a law, said Becky Dansky, legislative analyst for the national Marijuana Policy Project. The fastest state to set up dispensaries was Minnesota, which took about 13 months to open a narrow program; on the other hand, Maryland has no dispensaries open nearly five years after passing a law, she added.

“The idea of having dispensaries open in a year was extremely ambitious,” Dansky said of Hawaii.

Hawaii also faces unique challenges as an isolated island state with a small population, which makes opening a testing lab difficult.

“Everything’s inflated. Lease areas, getting expensive equipment shipped on-island, finding the space,” said Michael Rollins, chief administrative officer of PharmLabs, a lab based on Maui that is awaiting certification from the Department of Health.

Given Hawaii’s small population, it’s not a certainty that labs will earn enough revenue to cover costs, unlike Seattle, with its large population and laws permitting recreational marijuana, Dansky said. Some states with small populations, such as Rhode Island, do not require lab testing, she said.

Changes in Hawaii’s regulations are also complicating the process for labs that are trying to open, Rollins said. For example, labs were originally required to test for 700 different pesticides, but the rule was changed to require testing for about 150 pesticides, he said. “That changes what type of equipment you need,” he said.

State officials say they are waiting on documents from the three laboratories that have applied, and are likely to approve at least one lab sometime this summer. But they don’t want to rush and risk approving an unsafe product.

0 3774
marijuana-stocks-cryptocurrency

This morning, Vancouver based company First Bitcoin Capital Corp (BITCF) announced its second Initial Coin Offering (ICO). The cryptocurrency craze has been hot lately with many seeing uncapped potential within the market itself; bitcoin has taken a major role in this latest excitement. But now it looks like the marijuana industry could be ready to see a new currency, WEED.

First Bitcoin launched its first ICO for “Altcoin” and now has announced its second ICO for its cryptocurrency with a coin named WEED. There are similar currencies out there such as POTCOIN but obviously if you have anything called “WEED” in a marijuana related industry, it could become that much easier to identify. WEED coin takes advantage of the same Bitcoin Blockchain, Omni protocols as their previously launched Altcoin.

“WEED commemorates the global legalization of marijuana and is the next paradigm of money for all things cannabis” according to the company. There is one caveat though. Besides actually having an account to buy cryptocurrency, in order to purchase WEED, apparently traders will need to send a different coin (1 President Johnson coin -$GARY) to the company’s bitcoin wallet. 1 GARY is around $0.023 right now, where 1 bitcoin is about $2,825.

In the company’s press release, they specifically state that in order to insure receipt of the WEED coin upon transferring GARY to the company’s address, people will need to use their own personal Omni Wallet addresses and not an exchange provided wallet. The reason for this is that they may not be prepared to credit those WEED tokens to the senders’ accounts.

“Upon 6 confirmations, the WEED coins will safely arrive in your personal Omni Wallet. This process is fully automated and requires no manual processing by the issuer of WEED.”

So, it looks like two of the most speculative markets are converging with the launch of this latest ICO. We can only imagine what else will come of the growing marijuana industry as mainstream industry work to gain market share via a multitude of ways. This new cryptocurrency is just another example of how legal marijuana is attracting businesses of all shapes and sizes right now.

0 1017
medical-marijuana-cancer-treatment

Well, he did it again. Acting DEA chief Chuck Rosenberg restated his oft-voiced opinion recently that “marijuana is not medicine.”

The Washington Examiner stated that he told an audience at a clinic in Cleveland: “If it turns out that there is something in smoked marijuana that helps people, that’s awesome. I will be the last person to stand in the way of that… But let’s run it through the Food and Drug Administration process, and let’s stick to the science on it.”

Former Surgeon General Vivek Murthy, appearing along with Rosenberg, added: “Should we be reducing the administrative and other barriers to researching that in the government? 100 percent. But what we should not do is make policies based on guesswork. When we do that, what we do is put people at risk.”

This is all outrageous hypocrisy.

Surely Murthy is aware of the Catch-22: Government bodies like the National Institutes of Health won’t fund the very studies he is calling for due to the cannabis’ illegality. Nonetheless, there have certainly been studies—no “guesswork” is needed.

The Hill pointed out that results of a placebo-controlled, randomized clinical trial were just recently published in the New England Journal of Medicine, finding that administration of the cannabinoid CBD significantly reduces seizure frequency in children with an otherwise drug-resistant form of epilepsy.

The findings prompted the study’s lead author, Orrin Devinsky of New York University’s Langone Medical Center, to pronounce: “Cannabis is approved in 20 countries for spasms in multiple sclerosis, so to say there’s no evidence of efficacy is simply untrue… They have to de-schedule this drug. It’s just not fair to the research and clinical communities, or to the patients. It’s medieval.”

Ironically, the government has at times actually recognized such research on the medicinal value of cannabis and cannabinoids.

In 2003, the U.S. Department of Health and Human Services secured a patent—number 6630507—for the use of cannabinoids as antoxidants and neuroprotectants, with potential application in fighting cancer and degenerative diseases. Yet in 2006, a U.S. Food and Drug Administration memo reiterated the official dogma that cannabis has “no medical value.”

This is bureaucratic schizophrenia, which can only be overcome by freeing up the research and taking oversight out of the hands of the DEA, a law enforcement body.

The House bill to remove cannabis from the “schedule list” of controlled substances entirely could accomplish this. The good news is that it actually has a Republican sponsor, Rep. Tom Garrett of Virginia. But whether it can muster enough votes to survive a presidential veto seems dubious—and advocates are still waiting for a coherent Trump position on cannabis.

0 2214
marijuana-stocks-cannabis-canadian_flag

Canada plans to legalize recreational cannabis before July 1, 2018, and the industry continues to steal headlines as this has created great opportunity for both companies and investors.

Although the opportunity is significant, the process of becoming a licensed medical cannabis producer is very lengthy and expensive. These factors have resulted in the country having a supply and demand issue for the medical cannabis market.

Legal recreational cannabis is supposed to significantly increase the amount of cannabis in demand and Health Canada, which is responsible for the regulation of the medical cannabis market has made it easier for companies to get the required licenses.

Health Canada Streamlines Application Process

In late May, Health Canada announced that it has made some changes to streamline the application process to become a licensed medical cannabis producer. These changes will also increase overall production.

Since the licensing program came into effect in 2013, 45 medical marijuana production licenses have been granted (currently 428 companies applying to become licensed cannabis producers). Some of the changes announced by Health Canada include:

• The hiring of new employees to speed up the application process
• Permitting licensed producers to manage production based on their vault capacity
• Increased freedom to modify and expand their facilities

The biggest change announced by Health Canada pertains to production management. Under the new regulations, licensed producers can increase production within their facility to the maximum they are authorized to store, based on the capacity and security level of their vault(s) or safe(s). This will allow licensed producers to better manage production as necessary to meet demand.

Also, licensed producers will be able to store low-value cannabis waste products in a secure area outside of their vault. This will immediately impact the storage capacity of the LP’s, enabling increased production of finished cannabis products.

An Industry Ready to Bounce Back

Although these companies have been very attractive and profitable investment opportunities, they have been under significant pressure this year and the stocks have come well off its 2017 highs.

Several analysts warned cannabis investors about the massive investor fatigue plaguing cannabis licensed producers. One of the best way to protect yourself against this trend is by focusing on companies that have differentiated itself from its peers. We want to highlight five these companies and explain what and if they have a competitive advantage.

• Canopy Growth: The largest and most diverse licensed producer in Canada. The company has made two large acquisitions in the last two years (Bedrocan and Mettrum Health) and is an attractive stock due to its global presence (Australia, Canada, and Germany), its continued execution and track record, its improving fundamentals, and its management team.
• Aphria: One of the lowest cost producers due to its greenhouse production style. The company has made investments in the burgeoning United States cannabis industry and is levered to states like Arizona and Florida.
• Aurora Cannabis: One of the fastest growing licensed producers and has one of the strongest balance sheets when compared to its peers. Through acquisitions and investments, Aurora has become levered to international markets like Australia and Germany
• Cannabis Wheaton: Operates under a streaming model and does not actually touch the plant. Has secured deals with 17 producers across Canada. The shares have plunged after announcing a new financing deal and we continue to monitor trading after Cannabis Wheaton announced that Hugo Alves was appointed as President and Director of the company.
• Emblem Corp: The company is focused on two major markets. The development of biotech treatments derived from cannabis and the production of high-quality cannabis. Emblem has come off its recent lows and seems to have found a bottom. This is a stock to watch.

Disclaimer: Pursuant to an agreement between MAPH and Cannabis Wheaton (KWFLF) we were hired for 30 Days to publicly disseminate information about (KWFLF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for and were paid “0” shares of restricted common shares of Cannabis Wheaton. We may buy or sell additional shares of (KWFLF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Authored by: Michael Berger

0 1692
marijuana-stocks-cannabis-florida

State legislators reached an agreement to make medical marijuana available in Florida, ending an impasse that hindered the issue last month.

Reached Tuesday night after weeks of closed-door negotiations, the deal affirms the will of 71 percent of voters who approved a constitutional amendment to legalize medical marijuana back in November’s election that allowed patients with a host of conditions access to the drug.

Lawmakers plan to vote on the issue by week’s end. It could be one of the only bills to pass during a three-day special session that began Wednesday under a cloud of discord and fears that the Legislature may not accomplish its work on other issues.

New Rules For Florida’s Medical Marijuana Program

“Our constitutional duty is to ensure the availability and safe use of medical marijuana in the manner prescribed by Florida voters,” said Sen. Rob Bradley, R-Fleming Island, in a statement. “This patient-first legislation will expand access to this medicine while ensuring safety.”

Yet some supporters of the amendment, while pleased that lawmakers reached consensus on legalization, criticized what wasn’t included.

Take smoking. The bills (HB 5A, SB 8A) allow patients to buy and consume cannabis from licensed growers and consume it by “vaping,” as edibles or as oils. But both prohibit smoking the drug.

John Morgan, the Orlando trial lawyer and possible gubernatorial candidate who bankrolled the Amendment 2 campaign, said if the bill is signed into law, he plans to sue the state.

“Done is better than perfect and this is far from perfect,” he wrote in a post on the website Medium. “I will be suing the state to allow smoke. It was part of my amendment.”

If the legislation passes, lawmakers want the Department of Health to grant 10 new licenses, first to qualified nurseries that tried to get a license previously but were beaten out for the license by another company. They will join the existing seven growers that were licensed under a much more limited cannabis program the Legislature passed in 2014. The legislation would also expand who could use the drug.

0 2039
Marjuana-Stocks-cannabis biotech

Although we are very favorable on the opportunity for licensed medical cannabis producers, we continue to believe that biotech firms will be the greatest beneficiaries of the legal cannabis movement.

One company focused on this opportunity is Tetra Bio-Pharma (TBP.CN: CSE) (TBPMF: OTCQB) and today, the company’s subsidiary submitted a report on the safety and pharmacokinetics of PPP001 to Health Canada.

Following this announcement, Tetra is also preparing for a Phase 3 clinical trial in collaboration with Québec’s leading medical cannabis clinic, Santé Cannabis. Tetra expects to launch the Phase 3 clinical trial by the fourth quarter of 2017 or first quarter of 2018.

PPP001 is the first smokeable cannabis drug product being developed for the treatment of late-stage cancer patients with pain. The Phase 3 clinical trial will be performed by Santé Cannabis’ medical team.

A Multi-Billion-Dollar Market Opportunity

This is a major milestone for Tetra Bio-Pharma and we expect the market to respond favorably to this news, especially after yesterday’s volatile trading day.

Cancer pain is a massive market and provides Tetra with a great opportunity to penetrate a multi-billion-dollar market opportunity. According to Global Pain Management, approximately 50% of cancer patients suffer from pain and more than 600,000 of these patients suffer from moderate-to-severe pain. In the United States, there are more than 4 million cancer patients and this pain market is valued at more than $5 billion.

After a detailed review of the clinical data, Tetra announced that the safety data met its expectations and that the pharmacokinetic data demonstrated that the inhalation of PPP001 achieved the targeted plasma levels of THC that could potentially achieve pain relief in cancer patients. The results of the Phase I trial provided the information required by Santé Cannabis’ medical experts to design a Phase 3 clinical trial for cancer patients.

Tetra will be completing the research required to ensure that PPP001 conforms to the chemistry and manufacturing requirements under the Food and Drug regulations to secure its Notice of Compliance and a Drug Identification Number.

In late May, Tetra had a pre-submission consultation meeting with the Therapeutic Products Directorate (TPD) of Health Canada to brief the agency on the safety findings and pharmacokinetics of PPP001, and to discuss its clinical development program leading to the submission of a New Drug Submission for a first indication in advanced cancer patients with pain. Health Canada provided feedback and guidance on Tetra’s clinical development program and the proposed Phase III clinical trial.

An Execution Story

Less than a month ago, Tetra signed a definitive agreement with Panag Pharma for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. Tetra is focused on generating revenue in 2017 by launching retail products via its partnership with Panag.

Panag has developed potential new cannabinoid-based therapies for ocular and topical anti-inflammatory and pain markets. The company also developed a cannabinoid topical drug product for the local treatment of pain and inflammation. Under the agreement, Tetra will have the exclusive right to sell the ocular and topical drug products in North America with right of first negotiation for international markets. Tetra will also have a right of first negotiation for future cannabinoid-based products.

Tetra will work with Panag’s team to ensure a rapid and successful process leading to marketing authorization. Panag will continue to develop new novel products for unmet medical need and Tetra will focus on commercializing these products.

A Differentiated Opportunity

We are favorable on this update and expect to see the shares move considerably higher today. Tetra has continued to execute on its strategy and is focused on creating value for its shareholders.

Tetra offers investors leverage to a company that is levered to the burgeoning legal cannabis industry through an opportunity that is different from what is currently available. This is a company in the early innings of a massive growth cycle and one that we think needs to be watched.

Disclaimer: Pursuant to an agreement between MAPH and Tetra Bio-Pharma, we were hired for a period of 90 days to publicly disseminate information about (TBPMF) including on the Website and other media including Facebook and Twitter. We are being paid $75,000 (CASH) for and were paid 250,000 restricted common shares of Tetra Bio-Pharma. We may buy or sell additional shares of (TBPMF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 1854
marijuana-stocks-potentcy-testing

Producing your own cannabis-infused oils and tinctures for use in edibles can be a complex business. The potency of the herb you’re using can vary, and different oils will extract cannabinoids at different rates. Not knowing the strength of your recipe makes proper dosing of the final product a difficult endeavor.

Taking away that mystery was the goal of the founders of Engineered Medical Technologies, a small tech company in Northern California.

Bringing together expertise in medicine and technology, they set out to help a friend with a neurological disorder. She had been having challenges creating edible medical marijuana therapies with a dose strong enough to provide relief, without being too strong and causing undesired side effects. She needed a way to know just how strong each batch of infusion was.

Enter tCheck, the cannabinoid potency test lab that fits in the palm of your hand.

The tCheck Home Infusion Potency Tester uses a UV spectrometer to determine an aggregate total of all cannabinoids in a butter, oil or alcohol infusion. Just a couple drops in the test tray is all it takes. The tray is slid into the machine, which analyzes the sample, and returns results in less than one minute. A built-in calculator makes it easy to determine milligrams per milliliter, teaspoon or tablespoon.

The tCheck can measure cannabinoids up to a concentration of 15 percent for olive oil, 10 percent for butter and coconut oil and eight percent for alcohol. If your infusion is stronger than the upper limit, the instructions advise to dilute a sample by half and double the result received from a new test.

It’s important to note that the reading you get is the total of all cannabinoids, not just THC.

Using average cannabinoid ratios by strain, an online calculator from tCheck can help you determine approximate THC levels in your sample. Although only a few strains are currently included in the calculator, a custom entry function allows you to enter lab results or averages for the strain you used for your infusion. The calculator then provides the amount of infusion to use in your recipe to achieve the desired dose per serving.

This is where the Trump administration enters the story.

The strain specific calculator just mentioned used to be freely available on the website. I had checked it out when originally researching this story. But after I received my tCheck and tried it out for the first time, I attempted to interpret my results. I was confused, as the website no longer had any reference to THC or cannabinoids. Plus, the calculator no longer included any strain or cannabinoid ratio information.

Peichen Chang, co-founder of Engineered Medical Technologies, and Kelly Maynard, director of sales, explained that in mid-March, the company’s credit card processor notified them that their account would be closed within 72 hours, because of references to marijuana.

As reported by online magazine Inc., tCheck and other cannabis industry ancillary businesses were deemed too risky and dropped by multiple payment processors after statements made by Attorney General Jeff Sessions on February 28. Sessions hinted at a toughening stance on marijuana by the new administration at a gathering of the National Association of Attorneys General.

At that meeting, Sessions said “States can pass the laws they choose. I would just say, it does remain a violation of federal law to distribute marijuana throughout any place in the United States, whether a state legalizes it or not.”

Apparently, states’ rights are only an issue for the Trump administration when it’s convenient to their agenda.

After scrubbing their website and social media accounts of all references to cannabis, THC and other cannabinoids, tCheck secured the services of a new credit card processor. tCheck now provides customers access to the full, strain-specific cannabinoid calculator via a private, password protected page on its website.

With the politics of pot set aside, renewed access to the online calculator allowed me to approximate the amount of THC per serving for any recipe.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements